{
  "success": true,
  "pagesUsed": [
    2,
    3,
    4,
    5,
    6,
    7,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    19,
    20,
    21,
    22,
    24,
    25,
    26,
    27,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    40,
    41,
    42,
    43,
    44,
    45,
    46,
    47,
    48
  ],
  "modelUsed": "gpt-5.1",
  "interventions": {
    "studyInterventions": [
      {
        "id": "int_1",
        "name": "ALXN1840",
        "role": {
          "code": "Investigational Product",
          "codeSystem": "USDM",
          "decode": "Investigational Product"
        },
        "instanceType": "StudyIntervention",
        "description": "Oral bis-choline tetrathiomolybdate administered once daily at 15 mg and 30 mg doses to participants with Wilson disease",
        "productIds": [
          "prod_1"
        ],
        "administrationIds": [
          "admin_1"
        ]
      },
      {
        "id": "int_2",
        "name": "Copper- and molybdenum-controlled diet",
        "role": {
          "code": "Background Therapy",
          "codeSystem": "USDM",
          "decode": "Background Therapy"
        },
        "instanceType": "StudyIntervention",
        "description": "Standardized copper- and molybdenum-controlled meals provided during inpatient periods to control dietary copper and molybdenum intake",
        "administrationIds": [
          "admin_2"
        ]
      }
    ],
    "administrableProducts": [
      {
        "id": "prod_1",
        "name": "ALXN1840 tablets",
        "instanceType": "AdministrableProduct",
        "doseForm": {
          "code": "Tablet",
          "codeSystem": "USDM",
          "decode": "Tablet"
        },
        "strength": "15 mg ALXN1840 containing 7.8 mg tetrathiomolybdic acid",
        "substanceIds": [
          "sub_1"
        ],
        "manufacturer": "Alexion"
      }
    ],
    "administrations": [
      {
        "id": "admin_1",
        "name": "ALXN1840 15 mg once daily, Days 1–28",
        "instanceType": "Administration",
        "dose": "15 mg",
        "doseFrequency": "once daily",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "Day 1 through Day 28"
      },
      {
        "id": "admin_2",
        "name": "ALXN1840 30 mg once daily, Days 29–39",
        "instanceType": "Administration",
        "dose": "30 mg",
        "doseFrequency": "once daily",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "Day 29 through Day 39"
      },
      {
        "id": "admin_3",
        "name": "ALXN1840 15 mg once daily maintained beyond 4 weeks",
        "instanceType": "Administration",
        "dose": "15 mg",
        "doseFrequency": "once daily",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "Up to Day 39 if escalation to 30 mg is not performed for safety reasons"
      },
      {
        "id": "admin_4",
        "name": "ALXN1840 reduced dosing to 15 mg every other day (dose modification)",
        "instanceType": "Administration",
        "dose": "15 mg",
        "doseFrequency": "every other day",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "As needed per dose modification criteria"
      },
      {
        "id": "admin_5",
        "name": "ALXN1840 temporary interruption",
        "instanceType": "Administration",
        "dose": "0 mg (hold treatment)",
        "doseFrequency": "N/A",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "Until laboratory/safety parameters improve per protocol criteria"
      },
      {
        "id": "admin_6",
        "name": "ALXN1840 outpatient dosing",
        "instanceType": "Administration",
        "dose": "15 mg or 30 mg according to assigned dose",
        "doseFrequency": "once daily",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "Outpatient Period between Day 9 and Day 23 (may be extended up to an additional 14 days)"
      }
    ],
    "substances": [
      {
        "id": "sub_1",
        "name": "bis-choline tetrathiomolybdate",
        "instanceType": "Substance",
        "description": "Active pharmaceutical ingredient in ALXN1840; a copper-binding agent also referred to as tetrathiomolybdate"
      },
      {
        "id": "sub_2",
        "name": "tetrathiomolybdic acid",
        "instanceType": "Substance",
        "description": "Acid form providing the active anion tetrathiomolybdate in ALXN1840 tablets"
      },
      {
        "id": "sub_3",
        "name": "tetrathiomolybdate",
        "instanceType": "Substance",
        "description": "Active anion of ALXN1840 responsible for copper binding and decoppering effects"
      }
    ],
    "medicalDevices": [],
    "summary": {
      "interventionCount": 2,
      "productCount": 1,
      "deviceCount": 0
    }
  },
  "rawResponse": {
    "interventions": [
      {
        "name": "ALXN1840",
        "role": "Investigational Product",
        "description": "Oral bis-choline tetrathiomolybdate administered once daily at 15 mg and 30 mg doses to participants with Wilson disease"
      },
      {
        "name": "Copper- and molybdenum-controlled diet",
        "role": "Background Therapy",
        "description": "Standardized copper- and molybdenum-controlled meals provided during inpatient periods to control dietary copper and molybdenum intake"
      }
    ],
    "products": [
      {
        "name": "ALXN1840 tablets",
        "doseForm": "Tablet",
        "strength": "15 mg ALXN1840 containing 7.8 mg tetrathiomolybdic acid",
        "manufacturer": "Alexion"
      }
    ],
    "substances": [
      {
        "name": "bis-choline tetrathiomolybdate",
        "description": "Active pharmaceutical ingredient in ALXN1840; a copper-binding agent also referred to as tetrathiomolybdate",
        "codes": {}
      },
      {
        "name": "tetrathiomolybdic acid",
        "description": "Acid form providing the active anion tetrathiomolybdate in ALXN1840 tablets",
        "codes": {}
      },
      {
        "name": "tetrathiomolybdate",
        "description": "Active anion of ALXN1840 responsible for copper binding and decoppering effects",
        "codes": {}
      }
    ],
    "administrations": [
      {
        "name": "ALXN1840 15 mg once daily, Days 1–28",
        "dose": "15 mg",
        "frequency": "once daily",
        "route": "Oral",
        "duration": "Day 1 through Day 28",
        "instructions": "Administered as one 15 mg tablet after an overnight fast (at least 10 hours) at the same time every morning with 240 mL of water; meals delayed a minimum of 2 hours after dosing"
      },
      {
        "name": "ALXN1840 30 mg once daily, Days 29–39",
        "dose": "30 mg",
        "frequency": "once daily",
        "route": "Oral",
        "duration": "Day 29 through Day 39",
        "instructions": "Administered as two 15 mg tablets (total 30 mg) after an overnight fast at the same time every morning with 240 mL of water; meals delayed a minimum of 2 hours after dosing. Escalation contingent on Safety Review Committee review of safety data through Day 23"
      },
      {
        "name": "ALXN1840 15 mg once daily maintained beyond 4 weeks",
        "dose": "15 mg",
        "frequency": "once daily",
        "route": "Oral",
        "duration": "Up to Day 39 if escalation to 30 mg is not performed for safety reasons",
        "instructions": "Participants may remain on 15 mg/day for the duration of the study if, in the opinion of the Investigator and/or Alexion, escalation to 30 mg/day would place participants at undue risk"
      },
      {
        "name": "ALXN1840 reduced dosing to 15 mg every other day (dose modification)",
        "dose": "15 mg",
        "frequency": "every other day",
        "route": "Oral",
        "duration": "As needed per dose modification criteria",
        "instructions": "Dose range allowed by protocol for toxicity management is 15 mg every other day up to 30 mg/day. Used when criteria such as elevated ALT, anemia, thrombocytopenia, or neutropenia are met"
      },
      {
        "name": "ALXN1840 temporary interruption",
        "dose": "0 mg (hold treatment)",
        "frequency": "N/A",
        "route": "Oral",
        "duration": "Until laboratory/safety parameters improve per protocol criteria",
        "instructions": "Temporarily interrupt dosing when specified safety thresholds are reached (e.g., ALT >5× ULN or >5× increase from baseline, hemoglobin <8 g/dL, platelets <30,000/µL, neutrophils <1.0×10^3/µL), with weekly repeat testing and possible rechallenge at 15 mg every other day once parameters normalize"
      },
      {
        "name": "ALXN1840 outpatient dosing",
        "dose": "15 mg or 30 mg according to assigned dose",
        "frequency": "once daily",
        "route": "Oral",
        "duration": "Outpatient Period between Day 9 and Day 23 (may be extended up to an additional 14 days)",
        "instructions": "Participants self-administer ALXN1840 at approximately the same time daily (±1 hour) on an empty stomach with a glass of water; meals delayed at least 2 hours after dosing; SMS text messaging used to confirm administration"
      }
    ],
    "devices": []
  }
}